Trevi Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Trevi Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.76M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($47.91M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($29.07M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($29.15M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($33.94M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($32.76M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($26.05M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($20.55M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.33M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($51.52M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($33.92M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($29.91M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($32.48M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($32.49M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($26.65M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($18.41M) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.48M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $39.38M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $23.68M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $19.83M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $22.98M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $22.33M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $19.34M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $14.07M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.09M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($38.26M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($31.71M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($28.18M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($28.95M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($29.00M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($23.09M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($18.29M) | Mar 16, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.0K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $35.0K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $137.0K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $159.0K | Mar 20, 2024 |
| FY2021 | Dec 31, 2020 | $32.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $9.0K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $158.0K | Mar 16, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.44M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $110.90M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $89.40M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $123.02M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $38.48M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $47.13M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $60.00M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $10.53M | Mar 16, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.20M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $11.26M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $6.86M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $15.56M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $21.40M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $19.85M | Mar 17, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.24M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $99.64M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $82.55M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $107.46M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $17.08M | Mar 20, 2024 |
| FY2022 | Dec 31, 2020 | $27.28M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $54.55M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | ($109.49M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($84.43M) | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($329.80M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($287.05M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($239.13M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($210.07M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($180.92M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($146.98M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($114.22M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($109.50M) | Mar 16, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.91M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $34.10M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $32.40M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $12.59M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $36.83M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $45.00M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $57.31M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.20M | Mar 16, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 128.31M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 93.60M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 68.28M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 59.94M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 28.51M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 18.55M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 17.83M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 438,600 | Mar 16, 2020 |